FAQ: TransCode Therapeutics Completes Phase 1a Trial of TTX-MC138 and Advances to Phase 2

What is TTX-MC138 and what does it target?

TTX-MC138 is TransCode Therapeutics’ lead therapeutic candidate, an investigational inhibitor of microRNA-10b, which is a well-documented biomarker of metastasis. It’s designed to treat metastatic tumors that overexpress this specific microRNA.

What were the key results from the Phase 1a clinical trial?

The Phase 1a trial treated 16 patients with no significant safety events or dose-limiting toxicities observed, achieving its primary safety endpoint. Additionally, 44% of patients achieved stable disease lasting four months or longer, establishing a recommended Phase 2 dose.

Why is this clinical trial completion significant for cancer treatment?

This represents an important advancement in RNA therapeutics for metastatic cancer, demonstrating favorable safety, durability, and pharmacodynamic data that support moving to Phase 2 evaluation across multiple metastatic cancer indications.

What is TransCode Therapeutics’ focus and technology platform?

TransCode is a clinical-stage oncology company focused on treating metastatic disease through its proprietary TTX nanoparticle platform, which enables intelligent design and effective delivery of RNA therapeutics to overcome RNA delivery challenges.

What happens next for TTX-MC138 development?

Based on the successful Phase 1a results, TTX-MC138 will advance into a Phase 2a trial to further assess efficacy across multiple metastatic cancer indications, building on the established safety profile and recommended dose.

Where can investors find more information about TransCode Therapeutics?

The latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ, and the full press release can be viewed at https://ibn.fm/2gDqg.

What types of cancer is TTX-MC138 intended to treat?

TTX-MC138 is focused on treating metastatic tumors that overexpress microRNA-10b, with plans to assess efficacy across multiple metastatic cancer indications in the upcoming Phase 2a trial.

How does TransCode’s approach differ from traditional cancer treatments?

TransCode uses RNA therapeutics based on its proprietary TTX nanoparticle platform to target specific genetic markers like microRNA-10b, representing a novel approach focused on intelligent RNA design and delivery rather than conventional chemotherapy or radiation.